Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 20/20 | 0.54 |
| ▸ | THRA | P10827 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210106 | 0.86 | THRB (0.54) | THRBTHRA | |
| SCHEMBL13703184 | 0.85 | THRB (0.37) | THRBTHRA | |
| SCHEMBL13044572 | 0.83 | THRB (0.66) | THRBTHRA | |
| SCHEMBL13703182 | 0.80 | THRB (0.73) | THRBTHRA | |
| SCHEMBL13703158 | 0.79 | THRB (0.54) | THRBTHRA | |
| SCHEMBL3155779 | 0.78 | THRB (0.73) | THRBTHRA | |
| SCHEMBL13381925 | 0.77 | THRA (0.64) | THRBTHRA | |
| SCHEMBL13381932 | 0.77 | THRB (0.54) | THRBTHRA | |
| SCHEMBL13946878 | 0.77 | THRB (0.59) | THRBTHRA | |
| SCHEMBL13703163 | 0.77 | THRB (0.59) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | THRB 4/4885THRA 2/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRB 41/4885THRA 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.